Last $6.31 USD
Change Today -0.43 / -6.38%
Volume 64.4K
TNXP On Other Exchanges
As of 1:25 PM 01/28/15 All times are local (Market data is delayed by at least 15 minutes).

tonix pharmaceuticals holdin (TNXP) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/11/14 - $15.88
52 Week Low
10/20/14 - $5.33
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

tonix pharmaceuticals holdin (TNXP) Related Businessweek News

No Related Businessweek News Found

tonix pharmaceuticals holdin (TNXP) Details

Tonix Pharmaceuticals Holding Corp., a development stage specialty pharmaceutical company, focuses on the identification and development of pharmaceutical products for the disorders of central nervous system. The company’s lead product candidate, TNX-102 sublingual tablet, is a dosage formulation of cyclobenzaprine for the treatment of fibromyalgia and post-traumatic stress disorder. It also has a pipeline of various other product candidates, including TNX-201, which is a treatment for certain types of episodic tension-type headache; and TNX-301 that is indicated for the treatment of alcohol abuse and dependence. The company was founded in 2007 and is headquartered in New York, New York.

6 Employees
Last Reported Date: 03/28/14
Founded in 2007

tonix pharmaceuticals holdin (TNXP) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $277.5K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $314.2K
Chief Scientific Officer, Secretary and Contr...
Total Annual Compensation: $238.2K
Compensation as of Fiscal Year 2013.

tonix pharmaceuticals holdin (TNXP) Key Developments

Tonix Pharmaceuticals Holding Corp Announces Expiration of Employment Agreement with Donald Kellerman as Senior Vice President Clinical Development and Regulatory Affairs, Effective from March 31, 2015

On January 16, 2015, Tonix Pharmaceuticals Holding Corp. notified Donald Kellerman, the Company's Senior Vice President Clinical Development and Regulatory Affairs, that the Company would not renew Dr. Kellerman's employment agreement upon its expiration on March 31, 2015 and that his employment would terminate upon expiration of his employment agreement.

Tonix Pharmaceuticals Holding Corp. Commences Phase 2 Trial of TNX-102 SL in Post-Traumatic Stress Disorder

Tonix Pharmaceuticals Holding Corp. announced that the first participant in the AtEase study, sponsored by Tonix to evaluate TNX-102 SL for post-traumatic stress disorder, has received study medication. The AtEase study is a Phase 2 randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of TNX-102 SL in people with military-related PTSD and related conditions. The three-arm trial is expected to enroll approximately 220 participants, who will be randomized to receive two tablets of study medication to be taken sublingually at bedtime daily for 12 weeks. In the two active arms, participants will receive either one 2.8 mg TNX-102 SL tablet and one placebo tablet or 5.6 mg of TNX-102 SL (2 x 2.8 mg tablets). In the placebo comparator arm, participants will receive two placebo tablets. The primary endpoint of the trial is the week eight mean change from baseline in the total CAPS-5 (Clinician-Administered PTSD Scale) score in participants who received 2.8 mg of TNX-102 SL as compared to those who received placebo only. The safety of TNX-102 SL also will be evaluated. The trial is expected to be conducted at approximately 25 U.S. sites.

Tonix Pharmaceuticals Holding Corp Presents at Noble Financial Capital Markets Eleventh Annual Investor Conference, Jan-20-2015 03:30 PM

Tonix Pharmaceuticals Holding Corp Presents at Noble Financial Capital Markets Eleventh Annual Investor Conference, Jan-20-2015 03:30 PM. Venue: Club Med, Sandpiper Bay, Florida, United States. Speakers: Seth Lederman, Co-Founder, Chairman, Chief Executive Officer and President.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TNXP:US $6.31 USD -0.43

TNXP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TNXP.
View Industry Companies

Industry Analysis


Industry Average

Valuation TNXP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TONIX PHARMACEUTICALS HOLDIN, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at